234 related articles for article (PubMed ID: 35631687)
1. Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants.
Liu C; Rcheulishvili N; Shen Z; Papukashvili D; Xie F; Wang Z; Wang X; He Y; Wang PG
Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631687
[TBL] [Abstract][Full Text] [Related]
2. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
3. Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization.
Wang J; Zhang Y; Liu C; Zha W; Dong S; Wang Y; Jiang Y; Xing H; Li X
Mol Pharm; 2023 Oct; 20(10):4971-4983. PubMed ID: 37699256
[TBL] [Abstract][Full Text] [Related]
4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
5. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
Front Immunol; 2022; 13():908478. PubMed ID: 35844601
[TBL] [Abstract][Full Text] [Related]
7. A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants.
Lei Z; Zhu L; Pan P; Ruan Z; Gu Y; Xia X; Wang S; Ge W; Yao Y; Luo F; Xiao H; Guo J; Ding Q; Yin Z; Li Y; Luo Z; Zhang Q; Chen X; Wu J
J Med Virol; 2023 Feb; 95(2):e28475. PubMed ID: 36606607
[TBL] [Abstract][Full Text] [Related]
8. Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice.
Lu RM; Liang KH; Chiang HL; Hsu FF; Lin HT; Chen WY; Ke FY; Kumari M; Chou YC; Tao MH; Yi-Ling Lin ; Wu HC
Heliyon; 2023 May; 9(5):e15587. PubMed ID: 37090428
[TBL] [Abstract][Full Text] [Related]
9. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
10. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles.
Wang J; Zhang Y; Dong S; Zha W; Liu C; Wang Y; Jiang Y; Xing H; Li X
Int J Pharm; 2023 Jul; 642():123155. PubMed ID: 37402442
[TBL] [Abstract][Full Text] [Related]
11. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
12. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
13. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients.
Zhang L; Yang J; Lai C; Wan L; Xiong S; Kong W; Liu Z; Yu P; Chen M; Mai W; Khan SA; Deng M; Chen L; Lei Y; Zhou Q; Yu N; Li P; Chen Z; Ji T
Front Immunol; 2022; 13():1042784. PubMed ID: 36700230
[TBL] [Abstract][Full Text] [Related]
14. A Unique mRNA Vaccine Elicits Protective Efficacy against the SARS-CoV-2 Omicron Variant and SARS-CoV.
Guan X; Verma AK; Wang G; Roy A; Perlman S; Du L
Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932334
[TBL] [Abstract][Full Text] [Related]
15. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
[TBL] [Abstract][Full Text] [Related]
16. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.
Jiang L; Driedonks TAP; Jong WSP; Dhakal S; Bart van den Berg van Saparoea H; Sitaras I; Zhou R; Caputo C; Littlefield K; Lowman M; Chen M; Lima G; Gololobova O; Smith B; Mahairaki V; Riley Richardson M; Mulka KR; Lane AP; Klein SL; Pekosz A; Brayton C; Mankowski JL; Luirink J; Villano JS; Witwer KW
J Extracell Vesicles; 2022 Mar; 11(3):e12192. PubMed ID: 35289114
[TBL] [Abstract][Full Text] [Related]
17. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
[TBL] [Abstract][Full Text] [Related]
18. Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants.
Chen L; Qi X; Liang D; Li G; Peng X; Li X; Ke B; Zheng H; Liu Z; Ke C; Liao G; Liu L; Feng Q
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146579
[TBL] [Abstract][Full Text] [Related]
19. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
20. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice.
Sun W; He L; Zhang H; Tian X; Bai Z; Sun L; Yang L; Jia X; Bi Y; Luo T; Cheng G; Fan W; Liu W; Li J
Signal Transduct Target Ther; 2021 Sep; 6(1):340. PubMed ID: 34504054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
